ILC 2019: New studies in Germany and France support the need for early detection and effective interventions among NAFLD/NASH patients 11 April 2019, Vienna, Austria EASL (EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER) Two independent national studies have reported…
ILC 2019: Italian study reveals high cost of advanced liver disease in NAFLD/NASH patients and missed opportunities to diagnose earlier, yet screening high-risk individuals for NAFLD may not be cost effective if treatments are too expensive 11 April 2019, Vienna,…
ILC 2019: Interim analysis of the Phase 3 REGENERATE study suggests that obeticholic acid holds promise as a future treatment for NASH. 11 April 2019, Vienna, Austria EASL (EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER) A prespecified interim analysis…
ILC 2019: ‘Real-world’ studies in Germany and the USA confirm high rates of sustained virological response with sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) in individuals with chronic HCV infection failing DAAs 10 April 2019, Vienna, Austria EASL (EUROPEAN ASSOCIATION FOR THE STUDY OF THE…